AL

Alison Lawton

Director at X4 Pharmaceuticals

Alison Lawton joined the X4 Pharmaceuticals board of directors in October 2020. She has more than 30 years of experience in a wide range of senior executive and operational roles in the industry, with significant expertise across the full spectrum of drug development and commercialization activities. Ms. Lawton currently serves as a special advisor and board member at Kaleido Biosciences, Inc. and as an independent director of ProQR Therapeutics N.V. Previously, she served as Kaleido’s Chief Executive Officer, after initially joining the company as President and Chief Operating Officer. Prior to her time at Kaleido, Ms. Lawton was a member of X4’s corporate advisory board and served as consulting Chief Operating Officer. She also previously held Chief Operating Officer roles at Aura Biosciences and OvaScience Inc. Prior to this, Ms. Lawton spent more than 20 years at Genzyme Corporation. She served as Senior Vice President and General Manager of Sanofi Biosurgery, a $750 million business that included surgical, orthopedics, cell therapy and regenerative medicine franchises. Earlier, as Senior Vice President of Global Market Access for Genzyme, Ms. Lawton led global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Ms. Lawton began her career at Warner-Lambert/Parke-Davis, where she held several increasingly senior regulatory affairs positions. Additionally, she served two terms as the industry representative on the U.S. Food & Drug Administration’s (FDA) Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society (RAPS). Ms. Lawton also previously served as director on the boards of Verastem Inc., Cubist Pharmaceuticals, CoLucid Pharmaceuticals and Magenta Therapeutics. She earned her B.S. in pharmacology from King’s College London.

Links

Timeline

  • Director

    Current role